Multi-Stage Malaria Vaccine AdFalciVax
Kartavya Desk Staff
Source: TH
Context: The Union government has granted licences to five Indian firms to manufacture and commercialise AdFalciVax, the country’s first indigenous multi-stage malaria vaccine developed by ICMR.
About Multi-Stage Malaria Vaccine AdFalciVax:
• What it is?
• India’s first indigenous recombinant chimeric multi-stage malaria vaccine designed to block infection and transmission of Plasmodium falciparum, the deadliest malaria parasite.
• India’s first indigenous recombinant chimeric multi-stage malaria vaccine designed to block infection and transmission of Plasmodium falciparum, the deadliest malaria parasite.
• Developed by:
• ICMR–Regional Medical Research Centre (RMRC), Bhubaneswar, with support from ICMR–National Institute of Malaria Research (NIMR) and National Institute of Immunology (NII), New Delhi.
• ICMR–Regional Medical Research Centre (RMRC), Bhubaneswar, with support from ICMR–National Institute of Malaria Research (NIMR) and National Institute of Immunology (NII), New Delhi.
• To prevent infection in individuals and minimise community transmission of malaria, thereby aiding elimination goals.
• To prevent infection in individuals and minimise community transmission of malaria, thereby aiding elimination goals.
• Key Features:
• Targets parasite before it enters the bloodstream. Affordable, scalable, and stable → effective for over nine months at room temperature. Multi-stage action ensures protection at both infection and transmission stages. Successfully validated in pre-clinical trials.
• Targets parasite before it enters the bloodstream.
• Affordable, scalable, and stable → effective for over nine months at room temperature.
• Multi-stage action ensures protection at both infection and transmission stages.
• Successfully validated in pre-clinical trials.
• New Firms Licensed (2025):
• Indian Immunologicals Ltd, Techinvention Lifecare Pvt. Ltd, Panacea Biotec Ltd, Biological E Ltd, Zydus Lifesciences.
• Indian Immunologicals Ltd, Techinvention Lifecare Pvt. Ltd, Panacea Biotec Ltd, Biological E Ltd, Zydus Lifesciences.
• Significance:
• India carries 1.4% of global malaria cases and 66% of Southeast Asia’s burden. Boosts Atmanirbhar Bharat in health R&D by indigenising vaccine technology. Reduces dependence on imported vaccines and aligns with India’s Malaria Elimination Goal 2030.
• India carries 1.4% of global malaria cases and 66% of Southeast Asia’s burden.
• Boosts Atmanirbhar Bharat in health R&D by indigenising vaccine technology.
• Reduces dependence on imported vaccines and aligns with India’s Malaria Elimination Goal 2030.